Antibodies specific for either ras photo-oncogene encoded P21 proteins or ras oncogene encoded P21 proteins but not for both and method of producing same
US5300631A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 27, 1992 |
| Grant date | Apr 5, 1994 |
| Priority date | — |
| Expiry date | Jan 27, 2012 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T436/143333
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Experiments designed to define the differences between the pas p21 oncogene DNA isolated from human bladder cancer cells and its corresponding proto-oncogene are described herein. By a series of in vitro recombinations, the difference was initially isolated to a 350 kb segment of DNA; sequencing defined the difference as a change in the Gly.sup.12 codon causing the p21 protein of the oncogene to contain valine at a location where the p21 protein of the proto-oncogene contained glycine. Assays for detecting carcinogenesis based on such differences are also described. In one type of assay, a restriction enzyme specific for either the altered or non-altered DNA segment of the genes are employed to detect carcinogenesis. In another type of assay, serological reagents, such as antibodies specific for either p21 protein expressed from the proto-oncogene or p21 expressed from the oncogene, or a common site therein, are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.